Melatonin and diabetes: From pathophysiology to the treatment perspectives

5Citations
Citations of this article
9Readers
Mendeley users who have this article in their library.

Abstract

Pineal hormone melatonin synchronizes insulin secretion and glucose homeostasis with solar periods. Misalliance between melatoninmediated circadian rhythms and insulin secretion characterizes diabetes mellitus type 1 (T1DM) and type 2 (T2DM). Insulin deficiency in T1DM is accompanied by increased melatonin production. Conversely, T2DM is characterized by diminished melatonin secretion. In genome-wide association studies the variants of melatonin receptor MT2 gene (rs1387153 and rs10830963) were associated with fasting glucose, beta-cell function and T2DM. In experimental models of diabetes melatonin enhanced beta-cell proliferation and neogenesis, improved insulin resistance and alleviated oxidative stress in retina and kidneys. However, further investigation is required to assess the therapeutic value of melatonin in diabetic patients.

Cite

CITATION STYLE

APA

Konenkov, V. I., Klimontov, V. V., Michurina, S. V., Prudnikova, M. A., & Ishenko, I. J. (2013). Melatonin and diabetes: From pathophysiology to the treatment perspectives. Diabetes Mellitus, (2), 11–16. https://doi.org/10.14341/2072-0351-3751

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free